Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

30.41 +11.46 (+60.50%)
Streaming Delayed Price Updated: 11:52 AM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
Which stocks are gapping on Monday?
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data
Vera Therapeutics' share price surged over 65% during the pre-market trading session after the company released ORIGIN Phase 3 trial data. 
Via Benzinga
These stocks that are showing activity before the opening bell on Monday.
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
What's Going On With Vera Therapeutics Stock?
Vera Therapeutics shares are trading lower by 4.7% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109. 
Via Benzinga
Vera Therapeutics: Q4 Earnings Insights
Via Benzinga
(VERA) - Analyzing Vera Therapeutics's Short Interest
Via Benzinga
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this quarter to support 2025 FDA filing. 
Via Benzinga
Exposures Product Safety
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off This Quarter
Via Benzinga
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years
Vera Therapeutics announces ORIGIN Phase 2b trial data on atacicept, showing sustained IgAN improvement and kidney function stability over 96 weeks. 
Via Benzinga
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug
The company is working on a treatment for IgA nephropathy, a condition that affects how well the kidneys work. 
Via Investor's Business Daily
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Could This Stock Be the Next Biotech Buyout?
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning! 
Via InvestorPlace
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.